Dysautonomia in post-COVID-19 patients: new insights

Barizien, Nicolas; Guen, Morgan Le; Russel, S.; Touche, Pauline; Huang, Florent; Vallée, Alexandre

doi:10.21203/rs.3.rs-238032/v1

Cited by 2 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, we found that post-COVID-19-related dysautonomia increased patients' problems. Literature suggests that levels of fatigue is higher among patients with post-COVID-19 dysautonomia (Barizien et al, 2021;Chadda et al, 2022;Lo, 2021;Malik et al, 2022). Also, post-COVID-19 patients with dysautonomia showed reduced work rate and exercise (Ladlow et al, 2022).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Post-COVID-19 syndrome and related dysautonomia affect patients’ life and work productivity

Galanis

Katsiroumpa

Vraka

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: A significant percentage of COVID-19 patients experience post-COVID-19 symptoms and signs. Post-COVID-19 syndrome affects physical and mental health of patients in several ways. Aim: To investigate the impact of post-COVID-19 syndrome and related dysautonomia on patients life and work productivity. Methods: We conducted a cross-sectional study in Greece using an online questionnaire. Study population included 108 workers over 18 years old that have been diagnosed with post-COVID-19 syndrome. Patients were recruited from the Long COVID Greece patients society. We measured demographic and clinical characteristics of patients, resilience, and social support. Results: Among patients, 68.5% stated that post-COVID-19 syndrome affected their daily life to a great extent, 25% to a moderate level, and 6.5% to a small extent. Moreover, 56.5% stated that post-COVID-19 syndrome affected their work productivity to a great extent, 27.8% to a moderate level, and 15.7% to a small extent. Multivariable analysis identified that females and patients with post-COVID-19 dysautonomia had more problems in their daily life. Moreover, increased duration of COVID-19 symptoms was associated with increased daily problems. Increased resilience was related with fewer problems in daily life. Also, we found that patients with post-COVID-19 dysautonomia had less work productivity. Moreover, increased duration of COVID-19 symptoms was associated with more problems in work. Resilience was related with increased work productivity. Conclusions: Post-COVID-19 syndrome and related dysautonomia affect significantly patients daily and work life. Also, resilience is an important preventive factor improving patients life. Policy makers should develop and implement educational programs to improve patients life. Healthcare professionals should be aware of the post-COVID-19 syndrome and its consequences in order to understand post-COVID-19 patients and their problems.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Moreover, post-COVID-19-related dysautonomia increase physical complaints among patients causing fatigue, heart rate variability, and orthostatic hypotension (Barizien et al, 2021;Dani et al, 2021;Miglis et al, 2020).…”

Section: Introductionmentioning

confidence: 99%

Post-COVID-19 syndrome and related dysautonomia affect patients’ life and work productivity

Galanis

Katsiroumpa

Vraka

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Another study, published by Nicholas Barizien et al (2021), from France, with 39 participants without prior neurological complications from COVID-19 except for the loss of taste and smell, tested the hypothesis of dysautonomia among long COVID patients with fatigue. Heart-rate variability (HRV) with a change in position was used as a physiological marker for the evaluation of dysautonomia.…”

Section: Small-fiber Neuropathy and Long Covidmentioning

confidence: 99%

Role of Tau protein in long COVID and potential therapeutic targets

Marwaha

2023

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

IntroductionLong COVID is an emerging public health burden and has been defined as a syndrome with common symptoms of fatigue, shortness of breath, cognitive dysfunction, and others impacting day-to-day life, fluctuating or relapsing over, occurring for at least two months in patients with a history of probable or confirmed SARS CoV-2 infection; usually three months from the onset of illness and cannot be explained by an alternate diagnosis. The actual prevalence of long-term COVID-19 is unknown, but it is believed that more than 17 million patients in Europe may have suffered from it during pandemic.PathophysiologyCurrently, there is limited understanding of the pathophysiology of this syndrome, and multiple hypotheses have been proposed. Our literature review has shown studies reporting tau deposits in tissue samples of the brain from autopsies of COVID-19 patients compared to the control group, and the in-vitro human brain organoid model has shown aberrant phosphorylation of tau protein in response to SARS-CoV-2 infection. Tauopathies, a group of neurodegenerative disorders with the salient features of tau deposits, can manifest different symptoms based on the anatomical region of brain involvement and have been shown to affect the peripheral nervous system as well and explained even in rat model studies. Long COVID has more than 203 symptoms, with predominant symptoms of fatigue, dyspnea, and cognitive dysfunction, which tauopathy-induced CNS and peripheral nervous system dysfunction can explain. There have been no studies up till now to reveal the pathophysiology of long COVID. Based on our literature review, aberrant tau phosphorylation is a promising hypothesis that can be explored in future studies. Therapeutic approaches for tauopathies have multidimensional aspects, including targeting post-translational modifications, tau aggregation, and tau clearance through the autophagy process with the help of lysosomes, which can be potential targets for developing therapeutic interventions for the long COVID. In addition, future studies can attempt to find the tau proteins in CSF and use those as biomarkers for the long COVID.

show abstract

Dysautonomia in post-COVID-19 patients: new insights

Cited by 2 publications

References 24 publications

Post-COVID-19 syndrome and related dysautonomia affect patients’ life and work productivity

Post-COVID-19 syndrome and related dysautonomia affect patients’ life and work productivity

Role of Tau protein in long COVID and potential therapeutic targets

Contact Info

Product

Resources

About